Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 12/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.78 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.78 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.78 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.71 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259442 | 1.00 | AHCY (0.78) | AHCYHIF1ATMEM97SIGMAR1ADORA2B | |
| SCHEMBL5567792 | 0.91 | AHCY (0.78) | AHCYHIF1ATMEM97SIGMAR1ADORA2B | |
| SCHEMBL5567795 | 0.91 | AHCY (0.78) | AHCYHIF1ATMEM97SIGMAR1ADORA2B | |
| 5'-Carboxy Adenosine SCHEMBL2117257 | 0.88 | AHCY (1.00) | AHCYHIF1ATMEM97SIGMAR1ADORA2B | |
| 5'-Carboxy Adenosine SCHEMBL8981282 | 0.88 | AHCY (1.00) | AHCYHIF1ATMEM97SIGMAR1ADORA2B | |
| 5'-Carboxy Adenosine SCHEMBL2117314 | 0.88 | AHCY (1.00) | AHCYHIF1ATMEM97SIGMAR1ADORA2B | |
| 5'-Carboxy Adenosine SCHEMBL29376409 | 0.88 | AHCY (1.00) | AHCYHIF1ATMEM97SIGMAR1ADORA2B | |
| 5'-Carboxy Adenosine SCHEMBL3815016 | 0.88 | AHCY (1.00) | AHCYHIF1ATMEM97SIGMAR1ADORA2B | |
| SCHEMBL9410993 | 0.86 | AHCY (0.72) | AHCYHIF1ATMEM97SIGMAR1ADORA2B | |
| SCHEMBL784035 | 0.86 | AHCY (0.72) | AHCYHIF1ATMEM97SIGMAR1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133880-B2 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1802316-B1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-7863253-B2 | Purine Derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1996020-A2 | PURINE COMPOUNDS AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20070238694-A1 | Purine compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-11 | — | — | US | disclosed |
| WO-2007111954-A2 | PURINE COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHAMACEUTICALS CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1802316-A2 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060128652-A1 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2006-06-15 | — | — | US | disclosed |
| WO-2006034190-A2 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238694-A1 | Purine compounds and methods of use thereof | PNP, ADORA2A, P2RY1 | AHCY 142/4885HIF1A 512/4885TMEM97 3684/4885 |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | PNP, NUDT1, HPRT1 | AHCY 194/4885HIF1A 237/4885TMEM97 3969/4885 |
| US-20060128652-A1 | Purine derivatives and methods of use thereof | PNP, NUDT1, HPRT1 | AHCY 194/4885HIF1A 237/4885TMEM97 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.